Archive · 13 Aug 2025
Cohance Lifesciences Invests ₹230 mn in Hyderabad Facility
Cohance Lifesciences is building a new factory in India to make ingredients called oligonucleotides, used in new medicines.
They are investing ₹230 million.
The new facility will help them make more of these ingredients, moving from small lab experiments to large-scale production.
It will be able to produce up to 700 kg per year and has space to grow.
The company is working with customers and expects to start validating products for GMP use in 2026.
This investment is part of Cohance's plan to expand its production capabilities.
Cohance Lifesciences invested ₹230 million in a new cGMP oligonucleotide manufacturing facility in Hyderabad, India.
The facility will take chemistries from lab scale to commercial manufacturing.
The facility will have a GMP capacity of up to 700 kg annually, with room for expansion.
Customer engagements are underway, with audits planned in the coming quarters.
The investment complements the company's pilot and scale-up assets, expanding its role in next-generation therapeutics.
- Who
- Cohance Lifesciences
- What
- Cohance Lifesciences invested ₹230 million in a new cGMP oligonucleotide manufacturing facility.
- When
- Not specified in article.
- Where
- Hyderabad, India
- Why
- To meet the growing demand for oligonucleotide-based therapeutics.
- Company
- Cohance Lifesciences
- Investment Amount
- ₹230 million
- Facility Type
- cGMP oligonucleotide manufacturing
- Location
- Hyderabad, India
- Capacity
- Up to 700 kg annually
- Focus
- Oligonucleotide-based therapeutics
